nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2023 | editorial

Head and neck cancer revisited

verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Excerpt

Head and neck cancer (HNC) is a heterogenous disease involving multiple anatomical subsites such as the oral cavity, pharynx, and larynx. While incidence rates have been increasing during the last few decades, HNC remains the seventh most common cancer resulting in approximately 325,000 annual deaths globally [1]. Well-recognized risk factors for the development of HNC include alcohol consumption, smoking tobacco products, betel nut chewing, human papilloma virus (HPV), and Epstein–Barr virus (EBV) infections. …

Vorheriger Artikel American Society of Hematology meeting update

Nächster Artikel Long-term survival and follow-up care after cancer in Austria

Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780–6.CrossRefPubMedPubMedCentral

Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306–27.CrossRefPubMedPubMedCentral

Leemans CR, Tiwari R, Nauta JJ, et al. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73(1):187–90.CrossRefPubMed

Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104(12):946–54.CrossRefPubMed

Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–62.CrossRefPubMed

Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34(1):101–10.CrossRefPubMed

Machiels JP, Tao Y, Burtness B, et al. LBA5 primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022;33:S1399.CrossRef

Resl C, Georg P, Döller C. New developments in radiation oncology for head and neck cancers. memo. 2023;16(3).

Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.CrossRefPubMed

10.

Kocher F, Seeber A. Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma. memo. 2023; https://doi.org/10.1007/s12254-023-00901-5.CrossRef

11.

Yu H, Yin X, Mao Y, et al. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the global burden of disease study 2019. Eur Arch Otorhinolaryngol. 2022;279(3):1519–33.CrossRefPubMed

12.

Füreder T. Essential news of current guidelines: Nasopharyngeal carcinoma. memo. 2023; https://doi.org/10.1007/s12254-023-00903-3.CrossRef

Titel: Head and neck cancer revisited
verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder
Publikationsdatum: 01.09.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00907-z

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

ASH 2022—new developments in acute myeloid leukemia

American Society of Hematology meeting update

Late complications after oncological therapy

Lipid nanoparticles in the treatment of lung cancer—hype or hope?

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

Aggressive B cell lymphomas—highlights from ASH 2022